 | Up a level |
Poh, Mau Ern and Balakrishnan, Sivasubramaniam and Tan, Sin Nee and Abidin, Muhammad Adil Zainal and Liam, Chong Kin and Tan, Jiunn Liang and Pang, Yong Kek and Alaga, Arvindran and Tho, Lye Mun and How, Soon Hin (2024) Real-world efficacy of low dose osimertinib as second-line treatment in patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer. Translational Lung Cancer Research, 13 (7). pp. 1649-1659. ISSN 2218-6751, DOI https://doi.org/10.21037/tlcr-24-243.
Poh, Mau Ern and Chai, Chee Shee and Liam, Chong Kin and Ho, Gwo Fuang and Pang, Yong Kek and Hasbullah, Harissa Husainy and Tho, Lye Mun and Nor, Ibtisam Muhamad and Ho, Kean Fatt and Thiagarajan, Muthukkumaran and Samsudin, Azlina and Omar, Azza and Ong, Choo Khoon and Soon, Sing Yang and Tan, Sin Nee and How, Soon Hin (2024) Does dose reduction of afatinib affect treatment outcomes of patients with EGFR-mutant metastatic non-small cell lung cancer in real-world clinical practice? Translational Lung Cancer Research, 13 (2). pp. 307-320. ISSN 2218-6751, DOI https://doi.org/10.21037/tlcr-23-691.
How, Soon Hin and Liam, Chong Kin and Abidin, Muhammad Adil Zainal and Hasbullah, Harissa H. and Tho, Lye Mun and Ho, Gwo Fuang and Nor, Ibtisam Muhamad and Pang, Yong Kek and Ho, Kean Fatt and Thiagarajan, Muthukkumaran and Ariffin, Roziana and Samsudin, Azlina and Omar, Azza and Tan, Sin Nee and Ong, Choo Khoon and Soon, Sing Yang and Poh, Mau Ern (2022) Outcomes of patients with EGFR-mutant advanced NSCLC in a developing country in Southeast Asia. Cancer Management And Research, 14. pp. 1995-2005. ISSN 1179-1322, DOI https://doi.org/10.2147/CMAR.S364713.
